Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

Biogen has made a further push into RNA-based ... which is used as a template for protein synthesis in cells – is transformed into a mature form. As its name suggests, splicing involves snipping ...

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first ... that lead to low levels of frataxin, a protein necessary for the correct functioning of mitochondria ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.

Biogen shares soared 44 percent on a single ... drug slowed cognitive decline and the rate of accumulation of tau, a protein that creates tangles within brain cells. TD Cowen analyst Stacy Ku ...

Last Friday, Biogen offered to buy Sage Therapeutics ... an experimental drug that targets tau, a different protein found in the brains of Alzheimer's patients. "We are doubling down in Alzheimer ...